THE EFFECT OF MESENCHYMAL STEM CELLS FOR THE REDUCTION OF LIVER FIBROSIS THROUGH PLATELET DERIVED GROWTH FACTORâ REGULATION IN RATS.

Chronic Liver Disease (CLD) is associated with hepatocyte damage, massive inflammation and liver fibrosis, capable of promoting cancer. Although, majority of hepatocytes diminished in CLD, stem cell derived from circulating endogenous Mesenchymal Stem Cells (MSCs) plays several roles in the rapid regeneration process, through regulating serum Platelet Derived Growth Factor-β (PDGF-β) levels. The aim of this study was to analyze the effect of MSCs administration in the liver fibrosis of rats by measuring their serum PDGF-β level and histopatology appearance. MSCs was isolated from Sprague Dawley (SD) rats and the liver fibrosis induced with carbon tetrachloride (CCl4). In addition, MSCs (1 x 10⁶ cells) were intravenously injected 24 h after CCl4 with the Serum PDGF-β level determined by enzyme linked immunosorbent assay (ELISA) on day 3 and 14 after intravenous administration. Hematoxylin and eosin (H&E) staining was used to evaluate histopatology, while statistical analysis was performed with SPSS version 12.0. The obtained data were analyzed by one-way ANOVA with a LSD comparison post hoc test. MSCs treatment significantly increased serum PDGF-β level compared with the control group on day 3 ( p < 0.05), which was significantly reduced liver fibrosis on histopatology appearance on day 14 ( p < 0.01). Our study indicates that MSCs alleviate liver fibrosis through the PDGF-β regulation in rats. [ABSTRACT FROM AUTHOR]